Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index; 10 of the 61 sources its claims cite were checked for support.
Abstract
Superagonistic CD28 antibodies (CD28SAs) activate T lymphocytes without concomitant perturbation of the TCR/CD3-complex. In rodents these reagents induce the preferential expansion of regulatory T cells and can be used for the treatment of autoimmune diseases. Unexpectedly, the humanized CD28 superagonist TGN1412 caused severe and life threatening adverse effects during a recently conducted phase I clinical trail. The underlying molecular mechanisms are as yet unclear. We show that TGN1412 as well as the commercially available CD28 superagonist ANC28.1 induce a delayed but extremely sustained calcium response in human naïve and memory CD4+ T cells but not in cynomolgus T lymphocytes. The sustained Ca++-signal was associated with the activation of multiple intracellular signaling pathways and together these events culminated in the rapid de novo synthesis of high amounts of pro-inflammatory cytokines, most notably IFN-gamma and TNF-alpha. Importantly, sustained transmembranous calcium flux, activation of Src-kinases as well as activation of PI3K were found to be absolutely required for CD28SA-mediated production of IFN-gamma and IL-2. Collectively, our data suggest a molecular basis for the severe side effects caused by TGN1412 and impinge upon the relevance of non-human primates as preclinical models for reagents that are supposed to modify the function of human T cells.
Overview
CoChat Summary
TL;DR
Two anti-human CD28 superagonists, TGN1412 and ANC28.1, induce a delayed but extremely sustained calcium signal in human CD4+ T cells that drives multiple signaling pathways and rapid pro-inflammatory cytokine production. This response is not reproduced in cynomolgus or rhesus monkey T cells despite conserved CD28 extracellular domains, suggesting a molecular basis for TGN1412’s severe clinical side effects and questioning non-human primates as preclinical models.
Key findings
- ANC28.1 and TGN1412 induced a sustained Ca++ signal in human naïve and memory CD4+ T cells that lasted for more than six hours without significant decrease; conventional CD28 mAbs did not induce detectable Ca++ flux.
- CD28SA stimulation activated multiple pathways (Erk1/2, JNK, p38, AKT, GSK3β-1, NF-ATc1, IκBα) and led to rapid de novo cytokine synthesis; IFN-γ was detectable in culture supernatant already 90–120 minutes after stimulation.
- IFN-γ and IL-2 production required transmembranous calcium flux, Src-kinase activity, PI3K activity, and calcineurin/NF-AT signaling; EGTA, cycloheximide, PP2, cyclosporin A, Wortmannin, and LY294002 each abrogated these responses.
- Despite complete conservation of CD28 extracellular and cytoplasmic domains between human, rhesus, and cynomolgus monkeys, TGN1412 induced only a very low calcium signal in monkey T cells; sequencing of 14 rhesus and 11 cynomolgus monkeys found three non-conservative amino acid exchanges in the transmembrane region and one in the leader sequence.
Methods
- Human T cells were purified from healthy volunteers; monkey T cells were purified from Macaca mulatta and Macaca fascicularis blood.
- Proliferation was measured by [3H]-thymidine incorporation; signaling was assessed by phosphospecific western blotting; calcium responses were measured by Indo-1 flow cytometry and Fura2 live video microscopy; cytokines were measured by cytometric bead arrays and ELISA.
- CD28 cDNAs from 14 rhesus and 11 cynomolgus monkeys were sequenced and compared with human CD28; TGN1412 binding and T cell subsets were analyzed by FACS.
Limitations
- The paper states that it is unclear how transmembrane calcium flux is induced and maintained upon CD28SA stimulation, which kinase phosphorylates LAT, and whether PI3K regulates IL-2/IFN-γ via AKT; it also cannot exclude differences in CD28 microcluster assembly or dynamics.
- The paper notes that CD28SAs do not fully activate human T cells, as β1/β2-integrin activation, F-actin formation, and cell migration were not observed.
- Evident from the text: the mechanistic work is primarily in vitro with human and monkey T cells, and the proposed link to TGN1412’s clinical cytokine storm is inferential rather than directly demonstrated in vivo.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Sustained calcium flux, T cell proliferation, and T cell signaling upon TGN1412 treatment. (A) Freshly isolated human T cells were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 µg/ml; red triangle). For crosslinking, 20 µg/ml of monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca++-response was monitored. (B) 5×104 freshly prepared human T-cells/96-well were stimulated with the indicated concentrations of ANC28.1 or TGN1412 or were left untreated as a control. For crosslinking of ANC28.1, a polyclonal goat anti-mouse antiserum was used and crosslinking of TGN1412 was performed as described in (A). Concentrations for crosslinking were the following: 0.1–1.25 µg/ml primary Ab+2.5 µg/ml crosslinker; 2.5 µg/ml primary Ab+5 µg/ml crosslinker; 5 µg/ml primary Ab+10 µg/ml crosslinker; 10 µg/ml primary Ab+20 µg/ml crosslinker. 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. (C) 1×106 freshly prepared human T cells/lane were left untreated or were stimulated with 10 µg/ml ANC28.1 (first and third panel) followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum or with 10 µg/ml TGN1412 (right panel) followed by crosslinking as described in (A) for the indicated periods of time. As a control, cells were activated with a 1∶50 dilution of ascites fluid of CD3 mAb MEM92 (second panel). Postnuclear lysates were processed for western blotting using the indicated phosphospecific antibodies. Western blotting using an anti-actin antibody was performed as loading control.](https://figures.cochat.ai/paper-figures/9abb1f35781940be83230bd1813f743d/signaling-signatures-and-functional-properties-of-anti-human-cd28-superagonistic-figure-3.jpg)
![Figure 4 Cytokine production upon conventional and superagonistic CD28 stimulation of human T cells. 5×104 freshly prepared human T-cells/96-well were stimulated with the indicated combination of antibodies as described in Fig. 1A or were left untreated as controls. At 48 hours 50 µl culture supernatant was removed from each well. Supernatants obtained from 3 wells were pooled and cytokine content was determined using the Cytokine Bead Array from BD in signals per minute [spm] (black bars). Additionally, induction of T cell proliferation was monitored upon treatment with the indicated antibody combinations (gray bars). 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. Data represent the mean of 5 individual experiments.](https://figures.cochat.ai/paper-figures/0d5cb189a0f2466ba5320666f039e770/signaling-signatures-and-functional-properties-of-anti-human-cd28-superagonistic-figure-4.jpg)


Verification
Claims the paper makes
8 Valid · 3 Not valid · 33 Not checked · 105 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, in line with a recent report [33] we did not see obvious differences in CD28 cluster formation upon CD28SA vs. CD28 stimulation by confocal laserscanning microscopy (data not shown).”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Discussion
What the sources say
- Disputedcites [33] Sester U Wabnitz GH Kirchgessner H Samstag Y 2007 Ras/PI3Kinase/cofilin-independent activation of human CD45RA(+) and CD45RO(+) T cells by superagonistic CD28 stimulation. Eur J Immunol 37 2881 2891 17899554 sourceExperimental — accuracy not yet measured
The section “Incomplete receptor clustering after 5.11A1 stimulation” (page unavailable) reports an obvious difference: conventional CD3/CD28 stimulation produced large, polarized receptor clusters, whereas superagonistic CD28 stimulation produced only small clusters that did not coalesce at one pole. The “Capping” methods section confirms that the images were obtained by confocal laser-scanning microscopy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Note that a conventional CD28 antibody only induced the known activation of the AKT and the JNK pathways (data not shown and [31]).”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Results > Intracellular signaling events induced by ANC28.1 and TGN1412
What the sources say
- Supportedcites [31] Saez-Rodriguez J 2007 A comprehensive logical model provides insights into T-cell signaling; submitted for publication. PMC1950951 17722974 source
The Results (Analysis of the Logical Model; page not supplied) report that a non-superagonistic CD28 antibody induced sustained JNK phosphorylation and that CD28 alone selectively activated JNK, not ERK. The Figure 4 caption in the Results also reports CD28-induced PKB (AKT) activation. Together, these support the cited comparison of AKT and JNK pathway activation. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“While conventional CD28 mAbs bind CD28 close to the binding site of the natural CD28 ligands, CD80 and CD86, CD28 superagonists bind to a laterally exposed loop within the extracellular domain of CD28 [8].”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Introduction
What the sources say
- Supportedcites [8] Luhder F Huang Y Dennehy KM Guntermann C Muller I 2003 Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 197 955 966 12707299 PMC2193880 source
The Introduction states that conventional anti-CD28 mAbs bind at or close to the B7 binding site. The section on separation of epitopes likewise places the epitopes of two conventional mAbs close to that site. These passages support the attributed claim about proximity to the natural ligands’ binding site; page numbers were not supplied. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“(i) we show that (similar to rat T cells [12]) the Ca++-signal produced by ANC28.1 required expression of a functional TCR (Fig. 2B);”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Discussion
What the sources say
- Supportedcites [12] Dennehy KM Elias F Na SY Fischer KD Hunig T 2007 Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J Immunol 178 1363 1371 17237383 source
The Discussion (p. 7) states that a functional TCR is required for CD28-superagonist signaling. The Results (pp. 3–4) show that TCR-deficient cells did not respond to superagonist stimulation and identify Ca²⁺ flux as part of that signaling pathway. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In agreement with data obtained in rat T cells [12], ANC28.1 stimulation did not result in a detectable tyrosine phosphorylation of the protein tyrosine kinase ZAP70 (Fig. 1B, middle panel) although ZAP70 is believed to be primarily responsible for LAT phosphorylation upon TCR-stimulation.”
§ Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies > Discussion
What the sources say
- Partly supportedcites [12] Dennehy KM Elias F Na SY Fischer KD Hunig T 2007 Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J Immunol 178 1363 1371 17237383 sourceExperimental — accuracy not yet measured
The Results (p. 4) report that CD28-superagonist stimulation did not induce Zap-70 phosphorylation in human Jurkat T cells. The paper does not identify the antibody as ANC28.1 in the passages examined, so it supports the finding but not the claim about that specific antibody. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
86 more claims · 1 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- It may state two separate claims as one. 22
- Not yet classified. 20
- Probably not a substantial claim. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, it has been previously published that ANC28.1 induces greater or similar in vitro cytokine release than TGN1412 (Waibler et al., 2008), which is in contrast to our findings here that TGN1412 is far more potent than ANC28.1.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Waibler et al., 2008
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 3×
“These were associated with the induction of a cytokine storm, i.e. the release of high amounts of proinflammatory cytokines, most notably TNF-a and IFN-c [21].”
BackgroundInfluentialEvolutionary and biomedical insights from the rhesus macaque genome.
Gibbs, R. A., Rogers, J., Katze, M. G., Bumgarner, R., Weinstock, G. M., Mardis, E. R., Remington, K. A., Strausberg, R. L., Venter, J. C., Wilson, R. K., et al. (2007) · Science · doi:10.1126/science.1139247 · Cited by 1,403
Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293 · cited 1×
“According to the currently accepted model of T cell activation, two signals are required to fully activate resting naive T lymphocytes. The primary signal is provided by the clonotypic T cell receptor (TCR) after recognition of antigen/MHC-complexes on the surface of antigen presenting cells. However, this signal by i…”
BackgroundZhang, W., Sloan-Lancaster, J., Kitchen, J., Trible, R. P., & Samelson, L. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80901-0 · Cited by 1,267 · cited 1×
“The transmembrane adapter protein LAT (Linker for Activation of T cells) represents a 35 kDa polypeptide that is essential for T cell activation [23,24].”
BackgroundCalcium signalling in lymphocyte activation and disease
Feske, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2152 · Cited by 1,043 · cited 1×
“Moreover, it will be important to determine the functional roles of the recently identified ORAI1 and STIM proteins in CD28SA-induced transmembrane Caflux [40].”
BackgroundVarma, R., Campi, G., Yokosuka, T., Saito, T., & Dustin, M. L. (2006) · Immunity · doi:10.1016/j.immuni.2006.04.010 · Cited by 879
Calcium signaling mechanisms in T lymphocytes.
Lewis, R. S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.497 · Cited by 860 · cited 1×
“S1 and [27]) induced a rapid, strong, and transient rise in intracellular Ca whereas the CD28SA-mediated Ca-signal started delayed and was of lower intensity (Fig.”
BackgroundCD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775 · cited 1×
“. In mouse and human T cells the dimeric transmembrane glycoprotein CD28 represents the most important co-stimulatory molecule. Under physiological conditions CD28-derived signals alone are not capable of inducing T cell activation, whereas simultaneous engagement of the TCR and CD28 (e.g. by its natural ligands CD80…”
BackgroundEssential Role of LAT in T Cell Development
Zhang, W., Sommers, C. L., Burshtyn, D. N., Stebbins, C. C., DeJarnette, J. B., Trible, R. P., Grinberg, A., Tsay, H. C., Jacobs, H. M., Kessler, C. M., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80032-1 · Cited by 547 · cited 1×
“The transmembrane adapter protein LAT (Linker for Activation of T cells) represents a 35 kDa polypeptide that is essential for T cell activation [23,24].”
BackgroundUnifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.
Rudd, C. E., & Schneider, H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1131 · Cited by 392 · cited 1×
“(reviewed in [3,4]).”
A Logical Model Provides Insights into T Cell Receptor Signaling
Saez-Rodriguez, J., Simeoni, L., Lindquist, J. A., Hemenway, R., Bommhardt, U., Arndt, B., Haus, U.-U., Weismantel, R., Gilles, E. D., Klamt, S., et al. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030163 · Cited by 352
Self-citationStebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316 · cited 1×
“In line with previous data obtained using TGN1412 [32] Fig.”
ResultAkt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines
Kane, L. P., Andres, P. G., Howland, K. C., Abbas, A. K., & Weiss, A. (2001) · Nature Immunology · doi:10.1038/83144 · Cited by 316 · cited 2×
“This suggests that PI3K or its downstream effector AKT [34,35] is mandatory (although not sufficient) for CD28SA-mediated IFN-c production.”
BackgroundTransmembrane adaptor proteins: organizers of immunoreceptor signalling
Hořejší, V., Zhang, W., & Schraven, B. (2004) · Nature Reviews Immunology · doi:10.1038/nri1414 · Cited by 212 · cited 2×
“Upon engagement of the TCR/CD3-complex, phosphorylated LAT facilitates the activation of PLCc1 which in turn generates the second messenger molecules IP3 (Inositol-tris-phosphate) and DAG (Diacyloglycerol; reviewed in [25]).”
BackgroundSelf-citationA point mutation in CD28 distinguishes proliferative signals from survival signals.
Okkenhaug, K., Wu, L., Garza, K. M., La Rose, J., Khoo, W., Odermatt, B., Mak, T. W., Ohashi, P. S., & Rottapel, R. (2001) · Nature Immunology · doi:10.1038/86327 · Cited by 210
T-cell costimulation–biology, therapeutic potential, and challenges.
Sharpe, A. H., & Abbas, A. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068087 · Cited by 206 · cited 1×
“from stimulation of so called co-stimulatory molecules [1,2].”
BackgroundLoss of Siglec expression on T lymphocytes during human evolution
Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510484103 · Cited by 204 · cited 2×
“Importantly, a recent study showed that chimpanzee T cells are also less responsive towards in vitro stimulation than human T cells and it was suggested that this might be due to loss of Siglec expression on human T cells [45].”
BackgroundBeyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203 · cited 1×
“Studies in rat and mice have also shown that CD28 superagonists preferentially induce the expansion of regulatory T cells and therefore suggested that these antibodies can be used for the treatment of autoimmune diseases such as experimental autoimmune encephalomyelitis [13–20].”
BackgroundLühder, F., Huang, Y., Dennehy, K. M., Guntermann, C., Müller, I., Winkler, E., Kerkau, T., Ikemizu, S., Davis, S. J., Hanke, T., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021024 · Cited by 193 · cited 1×
“. These antibodies have collectively been termed mitogenic CD28 antibodies or CD28 superagonists. While conventional CD28 mAbs bind CD28 close to the binding site of the natural CD28 ligands, CD80 and CD86, CD28 superagonists bind to a laterally exposed loop within the extracellular domain of CD28”
BackgroundEfficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist
Lin, C., & Hünig, T. (2003) · European Journal of Immunology · doi:10.1002/eji.200323570 · Cited by 184 · cited 1×
“Studies in rat and mice have also shown that CD28 superagonists preferentially induce the expansion of regulatory T cells and therefore suggested that these antibodies can be used for the treatment of autoimmune diseases such as experimental autoimmune encephalomyelitis [13–20].”
BackgroundCD28 as a Molecular Amplifier Extending TCR Ligation and Signaling Capabilities
Michel, F., Attal-Bonnefoy, G., Mangino, G., Mise-Omata, S., & Acuto, O. (2001) · Immunity · doi:10.1016/s1074-7613(01)00244-8 · Cited by 179
CD28 ligation in T-cell activation: evidence for two signal transduction pathways.
Ledbetter, J., Imboden, J., Schieven, G., Grosmaire, L., Rabinovitch, P., Lindsten, T., Thompson, C., & June, C. (1990) · Blood · doi:10.1182/blood.v75.7.1531.1531 · Cited by 170
Tacke, M., Hanke, G., Hanke, T., & Hünig, T. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270136 · Cited by 163 · cited 1×
“By definition, CD28 superagonists induce polyclonal T cell activation in vitro without the need of concomitant stimulation of the TCR/CD3 complex [5,7].”
BackgroundEstablishing risk of human experimentation with drugs: lessons from TGN1412
Kenter, M., & Cohen, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69562-7 · Cited by 153 · cited 1×
“Furthermore, it was debated whether the extracellular domains of Macaca fascicularis (cynomolgus), Macaca mulatta (rhesus), and Homo sapiens CD28 show subtle differences on the protein level [37] [38].”
BackgroundDistinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation.
Abe, R., Vandenberghe, P., Craighead, N., Smoot, D. S., Lee, K. P., & June, C. H. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.3.985 · Cited by 120 · cited 2×
“It was shown previously that in mouse splenic T cells only CD4 but not CD8 T cells showed Ca-flux upon CD28 triggering [29] whereas within human PBMCs also CD8 cells were capable of Ca-release upon CD28 stimulation [30].”
BackgroundPoulin, B., Sekiya, F., & Rhee, S. G. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409590102 · Cited by 108 · cited 1×
“of PLCγ1 which correlates with its enzymatic activity”
BackgroundBeyersdorf, N., Hanke, T., Kerkau, T., & Hünig, T. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042564 · Cited by 98 · cited 1×
“Studies in rat and mice have also shown that CD28 superagonists preferentially induce the expansion of regulatory T cells and therefore suggested that these antibodies can be used for the treatment of autoimmune diseases such as experimental autoimmune encephalomyelitis [13–20].”
BackgroundBeyersdorf, N., Hanke, T., Kerkau, T., & Hünig, T. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.06.001 · Cited by 66 · cited 1×
“Studies in rat and mice have also shown that CD28 superagonists preferentially induce the expansion of regulatory T cells and therefore suggested that these antibodies can be used for the treatment of autoimmune diseases such as experimental autoimmune encephalomyelitis [13–20].”
BackgroundHanke, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69651-7 · Cited by 65 · cited 1×
“Furthermore, it was debated whether the extracellular domains of Macaca fascicularis (cynomolgus), Macaca mulatta (rhesus), and Homo sapiens CD28 show subtle differences on the protein level [37] [38].”
BackgroundCD28 superagonists: Mode of action and therapeutic potential
Hünig, T., & Dennehy, K. M. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.012 · Cited by 63 · cited 3×
“Previously, several groups have assessed the signaling events induced by anti-rat or anti-mouse CD28 superagonistic antibodies [5,6,8,11–13].”
BackgroundSchmidt, J., Elflein, K., Stienekemeier, M., Rodriguez-Palmero, M., Schneider, C., Toyka, K. V., Gold, R., & Hünig, T. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00182-6 · Cited by 59 · cited 1×
“Studies in rat and mice have also shown that CD28 superagonists preferentially induce the expansion of regulatory T cells and therefore suggested that these antibodies can be used for the treatment of autoimmune diseases such as experimental autoimmune encephalomyelitis [13–20].”
BackgroundKirchgessner, H., Dietrich, J., Scherer, J., Isomäki, P., Korinek, V., Hilgert, I., Bruyns, E., Leo, A., Cope, A. P., & Schraven, B. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1269 · Cited by 59 · cited 1×
“2 [22,46] or commercially available CD28.”
Self-citationDennehy, K. M., Elias, F., Na, S.-Y., Fischer, K.-D., Hünig, T., & Lühder, F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1363 · Cited by 45 · cited 21×
“This was of particular interest because a recent report suggested that in rat T cells CD28SA induced IL-2 production might not require PI3K activity [12].”
BackgroundResultInfluential(2006) · PubMed · Cited by 44
Siefken, R., Klein-Heßling, S., Serfling, E., Kurrle, R., & Schwinzer, R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1645 · Cited by 37
Dennehy, K. M. (2003) · International Immunology · doi:10.1093/intimm/dxg063 · Cited by 36 · cited 7×
“However, due to the low on-rate or the weak accessibility of the CD28 epitope detected by CD28SAs, the induction of Ca-flux in rat T cells required antibody pre-incubation for several hours [11].”
BackgroundInfluentialLarge‐scale expansion of rat CD4+ CD25+ Treg cells in the absence of T‐cell receptor stimulation
Beyersdorf, N., Balbach, K., Hünig, T., & Kerkau, T. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02455.x · Cited by 32 · cited 1×
“Studies in rat and mice have also shown that CD28 superagonists preferentially induce the expansion of regulatory T cells and therefore suggested that these antibodies can be used for the treatment of autoimmune diseases such as experimental autoimmune encephalomyelitis [13–20].”
BackgroundPantaleo, G., Olive, D., Harris, D., Poggi, A., Moretta, L., & Moretta, A. (1986) · European Journal of Immunology · doi:10.1002/eji.1830161228 · Cited by 28 · cited 3×
“However, they also suggested that CD28-mediated signals do not activate the PTK pathway [30], occur in the absence of TCR signals [30], do not lead to production of DAG [39], and also do not activate PKC.”
BackgroundIbegbu, C., Brodie‐Hill, A., Kourtis, A. P., Carter, A., McClure, H., Wei Chen, Z., & Nahmias, A. J. (2001) · Journal of Medical Primatology · doi:10.1034/j.1600-0684.2001.300601.x · Cited by 16 · cited 1×
“6B and [43,44]).”
Ross, S. E., Schraven, B., Goldman, F. D., Crabtree, J., & Koretzky, G. A. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1013 · Cited by 15 · cited 1×
“Downmodulation of the TCR by treatment of T cells with the CD3e mAb 2AD2A2 [28] (Fig.”
BackgroundSelf-citationSester, U., Wabnitz, G. H., Kirchgessner, H., & Samstag, Y. (2007) · European Journal of Immunology · doi:10.1002/eji.200737206 · Cited by 12 · cited 2×
“that CD28SAs still induce upregulation of CD69 in human T cells pretreated with Wortmannin or Ly294002 [33].”
BackgroundResultNunes, J., Bagnasco, M., Lopez, M., Lipcey, C., Mawas, C., & Olive, D. (1991) · Molecular Immunology · doi:10.1016/0161-5890(91)90156-e · Cited by 9 · cited 4×
“These differences might be due to the different cells that were investigated or to different CD28 antibody preparations (ascites fluid in [22] vs.”
BackgroundInfluentialBischof, A. (2000) · doi:10.1002/1521-4141(200003)30:3
Rodriguez-Palmero, M. (1999) · doi:10.1002/(sici)1521-4141(199912)29:12<3914::aid-immu3914>3.0.co;2-#
Sopper, S. (1997) · doi:10.1002/(sici)1097-0320(19971201)29:4<351::aid-cyto12>3.0.co;2-t
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
“, 2008), and the ability of this antibody to cause sustained calcium flux (Waibler et al., 2008), among many other hypotheses (Schraven and Kalinke, 2008).”
BackgroundDelivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
“…suggested that differences in human- and macaque TGN1412-driven responses are due to the expression of inhibitory Siglecs on non-human primate T-cells, which have been lost during human evolution, rendering them less responsive to in vitro stimulation (Nguyen et al., 2006; Waibler et al., 2008).”
BackgroundResultWu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez-Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 259
Metadata
- Authors
- Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B.
- Affiliations
- Paul Ehrlich Institut (DE)
- Otto-von-Guericke-Universität Magdeburg (DE)
- Corresponding author
- Kalinke, Ulrich
- Schraven, Burkhart
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-03-05
- Volume
- 3
- Issue
- 3
- Pages
- e1708
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2246163
- OpenAlex
- W2044984824
- Cited by
- 79
- References
- 46
- Citations by year
- 2026: 4 · 2025: 1 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 10 · 2015: 3 · 2014: 7 · 2013: 2 · 2012: 8
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (SFB 432)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- TGN1412, T cell activation, calcium signaling, interferon-gamma, TNF-α, interleukin-2, Src kinase, phosphatidylinositol 3-kinase, regulatory T cells, autoimmune disease therapy, adverse drug reactions, CD4+ T cells
- MeSH terms
- Animals, Antibodies, Monoclonal, Calcium, Flow Cytometry, Humans, Interferon-gamma, Interleukin-2, Lymphocyte Activation, Macaca fascicularis, Macaca mulatta, Quinuclidines, T-Lymphocytes, Tumor Necrosis Factor-alpha, Blotting, Western, Signal Transduction, CD28 Antigens, src-Family Kinases, Cell Proliferation, T-Lymphocytes, Regulatory, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.